BioCentury | Mar 11, 2021
Emerging Company Profile

Ventyx emerges with $114M to bring asset-centric immunology plays under one umbrella

...was focused on developing small molecule agonists of FXR.“That...
...S1PR1 modulatorsTARGETScGAS – cGAMP synthase FXR (NR1H4) – Farnesoid X receptor GSDMD...
BioCentury | Jan 5, 2021
Finance

Immuneering, Terns, Ikena raise crossover rounds as IPO queue stands to grow again

...half from a Phase IIa trial of FXR...
...Management and Bristol Myers Squibb Co. (NYSE:BMY).TARGETSFXR (NR1H4...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Dec 31, 2020
Distillery Therapeutics

ERR-α identified as target in diabetic and hypertensive kidney disease

DISEASE CATEGORY: Renal INDICATION: Renal damage Promoting expression of the nuclear receptor ERR-α could treat kidney disease associated with diabetes and hypertension. Levels of ERR-α mRNA  were lower in microdissected human kidney samples samples from patients...
BioCentury | Dec 11, 2020
Management Tracks

Founding Intercept CEO Pruzanski prepares to hand over the reins

...company and remain on its board.Pruzanski co-founded Intercept in 2002 with bile acid chemistry and FXR...
...division. Before that, he was SVP and COO of Sanofi’s U.S. pharmaceuticals unit.TARGETSFXR (NR1H4) - Farnesoid X receptor Jeff...
BioCentury | Nov 30, 2020
Management Tracks

New CMO and Takeda alum Palmer adds to Ascletis’ push into NASH

...IPO. Gannex has a trio of clinical drug candidates against three different targets, FASN, THR-β and FXR...
...round last year.The company’s five other NASH programs were discovered in-house.TARGETSFASN (FAS) – Fatty acid synthase FXR (NR1H4...
BioCentury | Oct 28, 2020
Distillery Therapeutics

Targeting the NMDA receptor-TRPM4 complex for neurodegeneration

DISEASE CATEGORY: Neurology INDICATION: Stroke; neurology Disruption of the NMDA receptor-TRPM4 complex could treat ischemic stroke and other neurodegenerative diseases with NMDA receptor involvement. In mouse hippocampal neurons deprived of oxygen and glucose or treated...
BioCentury | Sep 2, 2020
Deals

NASH therapy from Novartis adds 15th program to Boston Pharmaceuticals’ pipeline

...two of the most advanced candidates: a complete response letter for Ocaliva obeticholic acid, an FXR...
BioCentury | Aug 28, 2020
Product Development

Data Bytes: NASH pipeline still full despite high-profile setbacks

...experienced setbacks this year, and both the programs have candidates behind them in their classes: FXR...
...the Phase III RESOLVE-IT trial (see “Intercept: Surrogate Endpoint Not Enough”).Behind Ocaliva, at least nine other FXR...
...alphaPPAR ƍ –  Peroxisome proliferation activated receptor delta Amanda Micklus Intercept Pharmaceuticals Inc. Genfit S.A. Novartis AG Pfizer Inc. Inventiva S.A. Farnesoid X receptor (FXR) (NR1H4) Peroxisome...
BioCentury | Jul 1, 2020
Product Development

Histology data builds on growing confidence around Akero’s NASH candidate

...complete response letter issued to Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) by FDA on Monday for its FXR...
...“Surrogate Endpoint Not Enough” ). Targets FGF21 - Fibroblast growth factor 21 FXR (NR1H4) - Farnesoid X receptor Lauren...
Items per page:
1 - 10 of 446